tetano
Editor, Senior Moderator
Med J Aust
. 2022 Oct 3;217(7):368-378.
doi: 10.5694/mja2.51718.
Care for adults with COVID-19: living guidelines from the National COVID-19 Clinical Evidence Taskforce
Heath White[SUP] 1 [/SUP], Steve J McDonald[SUP] 1 [/SUP], Bridget Barber[SUP] 2 [/SUP], Joshua Davis[SUP] 3 4 [/SUP], Lucy Burr[SUP] 5 6 [/SUP], Priya Nair[SUP] 7 [/SUP], Sutapa Mukherjee[SUP] 8 [/SUP], Britta Tendal[SUP] 1 [/SUP], Julian Elliott[SUP] 1 [/SUP], Steven McGloughlin[SUP] 9 [/SUP], Tari Turner[SUP] 10 [/SUP]
Affiliations
Abstract
Introduction: The Australian National COVID-19 Clinical Evidence Taskforce was established in March 2020 to maintain up-to-date recommendations for the treatment of people with coronavirus disease 2019 (COVID-19). The original guideline (April 2020) has been continuously updated and expanded from nine to 176 recommendations, facilitated by the rapid identification, appraisal, and analysis of clinical trial findings and subsequent review by expert panels.
Main recommendations: In this article, we describe the recommendations for treating non-pregnant adults with COVID-19, as current on 1 August 2022 (version 61.0). The Taskforce has made specific recommendations for adults with severe/critical or mild disease, including definitions of disease severity, recommendations for therapy, COVID-19 prophylaxis, respiratory support, and supportive care.
Changes in management as a result of the guideline: The Taskforce currently recommends eight drug treatments for people with COVID-19 who do not require supplemental oxygen (inhaled corticosteroids, casirivimab/imdevimab, molnupiravir, nirmatrelvir/ritonavir, regdanvimab, remdesivir, sotrovimab, tixagevimab/cilgavimab) and six for those who require supplemental oxygen (systemic corticosteroids, remdesivir, tocilizumab, sarilumab, baricitinib, casirivimab/imdevimab). Based on evidence of their achieving no or only limited benefit, ten drug treatments or treatment combinations are not recommended; an additional 42 drug treatments should only be used in the context of randomised trials. Additional recommendations include support for the use of continuous positive airway pressure, prone positioning, and endotracheal intubation in patients whose condition is deteriorating, and prophylactic anticoagulation for preventing venous thromboembolism. The latest updates and full recommendations are available at www.covid19evidence.net.au.
Keywords: Antiviral agents; COVID-19; Primary health care; Public health.
. 2022 Oct 3;217(7):368-378.
doi: 10.5694/mja2.51718.
Care for adults with COVID-19: living guidelines from the National COVID-19 Clinical Evidence Taskforce
Heath White[SUP] 1 [/SUP], Steve J McDonald[SUP] 1 [/SUP], Bridget Barber[SUP] 2 [/SUP], Joshua Davis[SUP] 3 4 [/SUP], Lucy Burr[SUP] 5 6 [/SUP], Priya Nair[SUP] 7 [/SUP], Sutapa Mukherjee[SUP] 8 [/SUP], Britta Tendal[SUP] 1 [/SUP], Julian Elliott[SUP] 1 [/SUP], Steven McGloughlin[SUP] 9 [/SUP], Tari Turner[SUP] 10 [/SUP]
Affiliations
- PMID: 36150213
- DOI: 10.5694/mja2.51718
Abstract
Introduction: The Australian National COVID-19 Clinical Evidence Taskforce was established in March 2020 to maintain up-to-date recommendations for the treatment of people with coronavirus disease 2019 (COVID-19). The original guideline (April 2020) has been continuously updated and expanded from nine to 176 recommendations, facilitated by the rapid identification, appraisal, and analysis of clinical trial findings and subsequent review by expert panels.
Main recommendations: In this article, we describe the recommendations for treating non-pregnant adults with COVID-19, as current on 1 August 2022 (version 61.0). The Taskforce has made specific recommendations for adults with severe/critical or mild disease, including definitions of disease severity, recommendations for therapy, COVID-19 prophylaxis, respiratory support, and supportive care.
Changes in management as a result of the guideline: The Taskforce currently recommends eight drug treatments for people with COVID-19 who do not require supplemental oxygen (inhaled corticosteroids, casirivimab/imdevimab, molnupiravir, nirmatrelvir/ritonavir, regdanvimab, remdesivir, sotrovimab, tixagevimab/cilgavimab) and six for those who require supplemental oxygen (systemic corticosteroids, remdesivir, tocilizumab, sarilumab, baricitinib, casirivimab/imdevimab). Based on evidence of their achieving no or only limited benefit, ten drug treatments or treatment combinations are not recommended; an additional 42 drug treatments should only be used in the context of randomised trials. Additional recommendations include support for the use of continuous positive airway pressure, prone positioning, and endotracheal intubation in patients whose condition is deteriorating, and prophylactic anticoagulation for preventing venous thromboembolism. The latest updates and full recommendations are available at www.covid19evidence.net.au.
Keywords: Antiviral agents; COVID-19; Primary health care; Public health.